KaryoCreate: A CRISPR-based technology to study chromosome-specific aneuploidy by targeting human centromeres

KaryoCreate:一种基于 CRISPR 的技术,通过靶向人类着丝粒来研究染色体特异性非整倍体

阅读:4
作者:Nazario Bosco ,Aleah Goldberg ,Xin Zhao ,Joseph C Mays ,Pan Cheng ,Adam F Johnson ,Joy J Bianchi ,Cecilia Toscani ,Elena Di Tommaso ,Lizabeth Katsnelson ,Dania Annuar ,Sally Mei ,Roni E Faitelson ,Ilan Y Pesselev ,Kareem S Mohamed ,Angela Mermerian ,Elaine M Camacho-Hernandez ,Courtney A Gionco ,Julie Manikas ,Yi-Shuan Tseng ,Zhengxi Sun ,Somayeh Fani ,Sarah Keegan ,Scott M Lippman ,David Fenyö ,Simona Giunta ,Stefano Santaguida ,Teresa Davoli

Abstract

Aneuploidy, the presence of chromosome gains or losses, is a hallmark of cancer. Here, we describe KaryoCreate (karyotype CRISPR-engineered aneuploidy technology), a system that enables the generation of chromosome-specific aneuploidies by co-expression of an sgRNA targeting chromosome-specific CENPA-binding ɑ-satellite repeats together with dCas9 fused to mutant KNL1. We design unique and highly specific sgRNAs for 19 of the 24 chromosomes. Expression of these constructs leads to missegregation and induction of gains or losses of the targeted chromosome in cellular progeny, with an average efficiency of 8% for gains and 12% for losses (up to 20%) validated across 10 chromosomes. Using KaryoCreate in colon epithelial cells, we show that chromosome 18q loss, frequent in gastrointestinal cancers, promotes resistance to TGF-β, likely due to synergistic hemizygous deletion of multiple genes. Altogether, we describe an innovative technology to create and study chromosome missegregation and aneuploidy in the context of cancer and beyond.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。